STAT
MARCH 3, 2025
Specifically, the likelihood that Canada’s Drug Agency would recommend that the federal government, provinces, and territories fund coverage of medicines was six times higher for all drugs, other than cancer medicines.
STAT
JANUARY 5, 2024
The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx , leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. Prasco, a U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
NOVEMBER 15, 2022
But the drug was bought by Leadiant Biosciences which, by 2014, began raising the price in several countries before withdrawing the medicine from the market entirely the following year. There was a low-cost version available for decades. Continue to STAT+ to read the full story…
pharmaphorum
JANUARY 16, 2023
Since 2014, the repayment percentage detailed in the VPAS and predecessor the PPRS averaged at around 7%, but skyrocketed to 19% in 2022 ahead of a government-agreed cap at 15%, and rose again to 26.5% ” The post AbbVie, Lilly pull out of UK voluntary drug pricing agreement appeared first on. in 2022. .
FDA Law Blog: Biosimilars
MARCH 18, 2025
Even though the PTE provisions established in the Drug Price Competition and Patent Restoration Act are forty-plus years old, courts are still grappling with questions about how to best implement the Patent Term Extension. The plain text of 35 U.S.C.
pharmaphorum
MARCH 10, 2022
It says the price increases were imposed “as though a new version of Acthar came on the market in 2013, when in fact, it did not,” which allowed it to ignore all price increases prior to 2013 in its rebate calculations.
Safe Biologics
NOVEMBER 12, 2023
Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. Pitts ran in the Pittsburgh Post-Gazette, in which he highlighted his concerns with Medicare drug price-setting policies stemming from the Inflation Reduction Act (IRA), passed last year.
Expert insights. Personalized for you.
217 
Let's personalize your content